Sector News

Sanofi's for-sale generics unit is too pricey, or so says dropout bidder

March 22, 2018
Life sciences

As Sanofi presses ahead with the sale of its European generics business, a private equity firm has bowed out, saying the deal is too expensive, the Financial Times reported.

Nordic Capital has bowed out of the bidding due to “very high” expectations over price, the Financial Times reported. The firm had intended to team with another private equity outfit, Blackstone, to bid on a unit that could fetch €2 billion ($2.47 billion).

Sanofi has said it should be able to sign a deal by the third quarter, and FT has previously reported the company has narrowed its list of buyers to Brazil’s EMS and India’s Torrent Pharma, plus a handful of private equity firms. The companies are completing due diligence before new bids are due next month, according to FT’s sources.

Sanofi’s European generics business operates in 50 countries and sells drugs in disease areas including cardiovascular, central nervous system, gastrointestinal and metabolic disorders and more. The unit generated €760 million last year, a 4.9% decrease from 2016, Sanofi reported.

The French drug giant started talking about a sale for its European generics business way back in 2015.

The deal talks come as Sanofi continues to transform under CEO Olivier Brandicourt, who came on board in 2015 and has worked to zero in on five global business units. Between sell-offs and cost-cutting, the company aims save €1.5 billion in annual costs.

Already, Brandicourt has offloaded Sanofi’s animal health unit Merial in a 2016 asset swap with Boehringer Ingelheim, in return for BI’s consumer health business.

But Brandicourt hasn’t just slimmed down. This year, Sanofi shelled out $4.8 billion for nanobody biotech Ablynx and $11.6 billon for hemophilia-focused Bioverativ—buys the CEO recently said “dramatically reshape our portfolio in specialty care, giving us a leading position in hemophilia and other rare blood disorders, and significantly strengthens our R&D.”

The company tried to buy Actelion and Medivation last year, but lost out in those pursuits to Johnson & Johnson and Pfizer, respectively.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach